Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.

Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan YY, Yang P, Chapkin RS, Eckhardt BL, Ueno NT.

Oncogene. 2019 Mar;38(12):2135-2150. doi: 10.1038/s41388-018-0569-5. Epub 2018 Nov 20.

2.

Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.

Eckhardt BL, Gagliardi M, Iles L, Evans K, Ivan C, Liu X, Liu CG, Souza G, Rao A, Meric-Bernstam F, Ueno NT, Bartholomeusz GA.

PLoS One. 2018 May 16;13(5):e0195932. doi: 10.1371/journal.pone.0195932. eCollection 2018.

3.

Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs.

Steigedal TS, Toraskar J, Redvers RP, Valla M, Magnussen SN, Bofin AM, Opdahl S, Lundgren S, Eckhardt BL, Lamar JM, Doherty J, Hynes RO, Anderson RL, Svineng G.

Neoplasia. 2018 Apr;20(4):387-400. doi: 10.1016/j.neo.2018.02.008. Epub 2018 Mar 11.

4.

EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.

Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA Jr, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT.

Oncotarget. 2017 Jul 4;8(40):67904-67917. doi: 10.18632/oncotarget.18958. eCollection 2017 Sep 15.

5.

A target of potential RELAvance in inflammatory breast cancer.

Eckhardt BL, Ueno NT.

Oncotarget. 2017 Apr 18;8(16):25835-25836. doi: 10.18632/oncotarget.17109. No abstract available.

6.

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.

Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT.

Breast Cancer Res Treat. 2017 Jul;164(1):57-67. doi: 10.1007/s10549-017-4233-5. Epub 2017 Apr 17.

PMID:
28417335
7.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

8.

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT.

Oncotarget. 2015 May 30;6(15):12890-908. Review.

9.

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.

Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RS, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, Restall CM, Lucas E, Pearson HB, Deb S, Britt KL, Rizzitelli A, Li J, Harmey JH, Pouliot N, Anderson RL.

Dis Model Mech. 2015 Mar;8(3):237-51. doi: 10.1242/dmm.017830. Epub 2015 Jan 29.

10.

BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL, Anderson RL.

Cancer Res. 2014 Sep 15;74(18):5091-102. doi: 10.1158/0008-5472.CAN-13-3171.

11.

Inhibition of established micrometastases by targeted drug delivery via cell surface-associated GRP78.

Miao YR, Eckhardt BL, Cao Y, Pasqualini R, Argani P, Arap W, Ramsay RG, Anderson RL.

Clin Cancer Res. 2013 Apr 15;19(8):2107-16. doi: 10.1158/1078-0432.CCR-12-2991. Epub 2013 Mar 7.

12.

Strategies for the discovery and development of therapies for metastatic breast cancer.

Eckhardt BL, Francis PA, Parker BS, Anderson RL.

Nat Rev Drug Discov. 2012 Jun 1;11(6):479-97. doi: 10.1038/nrd2372. Review.

PMID:
22653217
13.

Poly (A)+ transcriptome assessment of ERBB2-induced alterations in breast cell lines.

Carraro DM, Ferreira EN, de Campos Molina G, Puga RD, Abrantes EF, Trapé AP, Eckhardt BL, Nunes DN, Brentani MM, Arap W, Pasqualini R, Brentani H, Dias-Neto E, Brentani RR.

PLoS One. 2011;6(6):e21022. doi: 10.1371/journal.pone.0021022. Epub 2011 Jun 22. Erratum in: PLoS One. 2011;6(7). doi:10.1371/annotation/b8888ae6-e402-43af-a425-6fd5e58deef6. Ekhardt, Bedrich L [corrected to Eckhardt, Bedrich L].

14.

Targeting neuropilin-1 in human leukemia and lymphoma.

Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R.

Blood. 2011 Jan 20;117(3):920-7. doi: 10.1182/blood-2010-05-282921. Epub 2010 Nov 9.

15.

2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer.

Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG.

Clin Cancer Res. 2005 Mar 1;11(5):1722-32.

16.

Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix.

Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL.

Mol Cancer Res. 2005 Jan;3(1):1-13.

17.

Metallothionein-III inhibits initial neurite formation in developing neurons as well as postinjury, regenerative neurite sprouting.

Chung RS, Vickers JC, Chuah MI, Eckhardt BL, West AK.

Exp Neurol. 2002 Nov;178(1):1-12.

PMID:
12460603
18.

Sheep have an unusual variant of the brain-specific metallothionein, metallothionein-III.

Chung RS, Holloway AF, Eckhardt BL, Harris JA, Vickers JC, Chuah MI, West AK.

Biochem J. 2002 Jul 1;365(Pt 1):323-8. Erratum in: Biochem J 2002 Aug 1;365(Pt 3):903.

Supplemental Content

Loading ...
Support Center